Cargando…

Correction: Development and validation of a genomic mutation signature to predict response to PD-1 inhibitors in non-squamous NSCLC: a multicohort study

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7497552/ https://www.ncbi.nlm.nih.gov/pubmed/32938626 http://dx.doi.org/10.1136/jitc-2019-000381corr1

Ejemplares similares

Development and validation of a genomic mutation signature to predict response to PD-1 inhibitors in non-squamous NSCLC: a multicohort study
por: Bai, Xue, et al.
Publicado: (2020)

Author Correction: Development and validation of a risk prediction model for work disability: multicohort study
por: Airaksinen, Jaakko, et al.
Publicado: (2018)

Correction to: Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy
por: Brogden, Kim A., et al.
Publicado: (2018)

Erratum to: Development and validation of two SCORE-based cardiovascular risk prediction models for Eastern Europe: a multicohort study
Publicado: (2020)

Multicohort and cross‐platform validation of a prognostic Wnt signature in colorectal cancer
por: Goeman, Frauke, et al.
Publicado: (2020)

Identification and validation of a genomic mutation signature as a predictor for immunotherapy in NSCLC
por: Wang, Zemin, et al.
Publicado: (2022)

Genomic Analyses Reveal Mutational Signatures and Frequently Altered Genes in Esophageal Squamous Cell Carcinoma
por: Zhang, Ling, et al.
Publicado: (2020)

Genomic Analyses Reveal Mutational Signatures and Frequently Altered Genes in Esophageal Squamous Cell Carcinoma
por: Zhang, Ling, et al.
Publicado: (2020)

Development and validation of a risk prediction model for work disability: multicohort study
por: Airaksinen, Jaakko, et al.
Publicado: (2017)

Correction to: Molecular signature comprising 11 platelet-genes enables accurate blood-based diagnosis of NSCLC
por: Goswami, Chitrita, et al.
Publicado: (2020)

Correction: Antibody response, associated symptoms and profile of patients presumably infected by SARS-CoV-2 with taste or smell disorders in the SAPRIS multicohort study
por: Ramillon, Julien, et al.
Publicado: (2023)

Correction to: Efficacy of single-site radiotherapy plus PD-1 inhibitors vs PD-1 inhibitors for oligometastatic non-small cell lung cancer
por: Wang, Peiliang, et al.
Publicado: (2021)

Correction to: Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
por: Lamb, Yvette N.
Publicado: (2021)

Predictive value of tumor mutational burden for PD-1/PD-L1 inhibitors in NSCLC: A meta-analysis
por: Li, Wenjie, et al.
Publicado: (2023)

Identification and validation of tissue or ctDNA PTPRD phosphatase domain deleterious mutations as prognostic and predictive biomarkers for immune checkpoint inhibitors in non-squamous NSCLC
por: Sun, Yiting, et al.
Publicado: (2021)

Correction: Effect of body tissue composition on the outcome of patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors
por: Makrakis, Dimitrios, et al.
Publicado: (2023)

A 5-Genomic Mutation Signature Can Predict the Survival for Patients With NSCLC Receiving Atezolizumab
por: Lin, Jiamao, et al.
Publicado: (2021)

Correction: The Genomic Signature of Crop-Wild Introgression in Maize
por: Hufford, Matthew B., et al.
Publicado: (2013)

Correction to: Afatinib in advanced NSCLC: a profile of its use
por: Deeks, Emma D., et al.
Publicado: (2018)

Correction to: Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
por: Ren, Daixi, et al.
Publicado: (2020)

Author Correction: The repertoire of mutational signatures in human cancer
por: Alexandrov, Ludmil B., et al.
Publicado: (2023)

Correction: Novel Insight into Mutational Landscape of Head and Neck Squamous Cell Carcinoma
por: Gaykalova, Daria A., et al.
Publicado: (2020)

Development and validation of two SCORE-based cardiovascular risk prediction models for Eastern Europe: a multicohort study
por: Tillmann, Taavi, et al.
Publicado: (2020)

Correction: A Small Set of Succinct Signature Patterns Distinguishes Chinese and Non-Chinese HIV-1 Genomes
por: Wang, Yan, et al.
Publicado: (2013)

Correction: Development and validation of nomograms for predicting survival in patients with non-metastatic colorectal cancer
por: Jiang, Huihong, et al.
Publicado: (2018)

Multicohort analysis of the maternal age effect on recombination
por: Martin, Hilary C., et al.
Publicado: (2015)

Correction: Integrative Genomics Identifies Gene Signature Associated with Melanoma Ulceration
por: Rakosy, Zsuzsa, et al.
Publicado: (2013)

Correction: Identification and Chronological Analysis of Genomic Signatures in Influenza A Viruses
Publicado: (2014)

Predictive mutation signature of immunotherapy benefits in NSCLC based on machine learning algorithms
por: Liu, Zhichao, et al.
Publicado: (2022)

Correction: Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma
Publicado: (2020)

Correction to: Predicting the accuracy of genomic predictions
por: Dekkers, Jack C. M., et al.
Publicado: (2021)

Author Correction: Real-world evidence and clinical observations of the treatment of advanced non-small cell lung cancer with PD-1/PD-L1 inhibitors
por: Song, Peng, et al.
Publicado: (2020)

Multicohort Analysis Identifies Monocyte Gene Signatures to Accurately Monitor Subset-Specific Changes in Human Diseases
por: Vallania, Francesco, et al.
Publicado: (2021)

Multicohort transcriptome analysis of whole blood identifies robust human response signatures in Plasmodium falciparum infections
por: Zhang, Yan-hui, et al.
Publicado: (2022)

Correction to: Entrectinib: A Review in NTRK+ Solid Tumours and ROS1+ NSCLC
por: Frampton, James E.
Publicado: (2021)

Correction: Validation of a hypoxia related gene signature in multiple soft tissue sarcoma cohorts
por: Yang, Lingjian, et al.
Publicado: (2019)

Correction: Dynamic metrics-based biomarkers to predict responders to anti-PD-1 immunotherapy
por: Liu, Can, et al.
Publicado: (2019)

Correction to: Dynamic serum biomarkers to predict the efficacy of PD-1 in patients with nasopharyngeal carcinoma
por: Zhang, Ao, et al.
Publicado: (2021)

Association of clock-like mutational signature with immune checkpoint inhibitor outcome in patients with melanoma and NSCLC
por: Chong, Wei, et al.
Publicado: (2020)

Correction to: Osimertinib as first-line therapy in advanced NSCLC: a profile of its use
por: Scott, Lesley J.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_792i6k5isjge2985og1j37pc0n